Iron Deficiency Anemia Therapy Market Forecast 2026–2030 Highlighting Expansion Across Industries
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Will The Market Value Of The Iron Deficiency Anemia Therapy Market Grow Between 2026 And 2030?
The iron deficiency anemia therapy market has shown significant expansion in recent years. It is anticipated to increase from $4.78 billion in 2025 to $5.15 billion in 2026, at a compound annual growth rate (CAGR) of 7.8%. This historical market growth is due to several factors, including the rising prevalence of iron deficiency anemia, increased awareness of anemia management, the broader implementation of hospital-based treatment protocols, the growing consumption of oral iron supplements, and advancements in diagnostic screening for anemia.
The iron deficiency anemia therapy market is projected to experience robust expansion in the coming years. Its size is expected to climb to $6.92 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.6%. This anticipated growth during the forecast period is influenced by factors such as the increasing demand for quicker anemia correction, a rise in chronic diseases that cause anemia, the establishment of more specialty anemia clinics, a heightened focus on maternal and pediatric anemia care, and ongoing advancements in iron formulation technologies. Significant trends for this period include a greater adoption of intravenous iron therapies, a growing call for targeted anemia treatments, an increasing emphasis on patient-specific therapy regimens, the expansion of combination oral and parenteral therapies, and an enhanced focus on both treatment efficacy and safety.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Drivers Are Supporting The Iron Deficiency Anemia Therapy Market Growth?
The future expansion of the iron deficiency anemia therapy market is anticipated to be driven by a rising incidence of chronic ailments. These are defined as enduring medical conditions, typically lasting a year or longer. An increase in chronic illnesses stems from a growing occurrence of unhealthy habits, such as inadequate diet, insufficient exercise, and tobacco use, leading to conditions like obesity, diabetes, and cardiovascular issues, and subsequently, prolonged health problems. Such long-term conditions can escalate the demand for iron deficiency anemia therapy because they impair the body’s proper iron absorption, thereby elevating the likelihood of iron deficiency and making supplementation or treatment essential to re-establish iron levels. As an illustration, data from June 2024 by the National Health Service, a UK government body, revealed that 3,615,330 individuals registered with a GP received a diagnosis of non-diabetic hyperglycemia (pre-diabetes) in 2023. This represented an 18% surge compared to 3,065,825 cases recorded in 2022. Consequently, the expanding number of chronic disease cases is a key driver for the growth of the iron deficiency anemia therapy market.
Which Segment Categories Are Included In The Iron Deficiency Anemia Therapy Market Segment Analysis?
The iron deficiency anemia therapy market covered in this report is segmented –
1) By Product Type: Ferrous Sulphate, Ferrous Gluconate, Ferrous Fumerate, Ferric Hydroxide
2) By Therapy Type: Parenteral Iron Therapy, Oral Iron Therapy, Red Blood Cell Transfusion, Other Therapy Types
3) By Therapy Areas: Inflammatory Bowel Diseases, Renal Diseases, Obstetrics and Gynecology, Congestive Heart Failure, Oncology
4) By Distribution channel: Hospital Pharmacy, Drug Stores And Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Speciality Clinics, Home Care Setting, Other End Users
Subsegments:
1) By Ferrous Sulphate: Oral Ferrous Sulphate Tablets, Oral Liquid Ferrous Sulphate, Intravenous Ferrous Sulphate, Extended Or Delayed Release Formulations
2) By Ferrous Gluconate: Oral Tablets, Chewable Tablets, Liquid Solutions, Pediatric Formulations
3) By Ferrous Fumarate: Oral Tablets Or Capsules, Prenatal Supplements, Multivitamin with Iron Formulations, Pediatric Drops Or Syrups
4) By Ferric Hydroxide: Intravenous Iron Therapy, Ferric Hydroxide Polymaltose Complex, Dialysis-Specific Iron Therapy, Hospital-Based Injectable Formulations
Which Trends Are Expected To Impact The Iron Deficiency Anemia Therapy Market?
Leading companies in the iron deficiency anemia therapy market are increasingly focusing on developing advanced treatment options, such as injectable formulations, to improve both treatment effectiveness and patient access. A new injectable formulation refers to a drug version recently developed or modified for administration via injection. For example, in May 2023, Emcure Pharmaceuticals Ltd., an Indian-based pharmaceutical company, introduced Orofer FCM 750, a ferric carboxymaltose (FCM) formulation designed to address iron deficiency and iron deficiency anemia (IDA). Its advantages include enhanced patient compliance due to less frequent dosing compared to oral supplements. The product’s objective is to effectively manage iron deficiency anemia, particularly for individuals unable to tolerate oral iron supplements. This 750 mg/15 ml injectable ferric carboxymaltose gained approval from India’s DCGI for treating IDA in patients unresponsive to oral iron, especially pregnant women with hemoglobin <10 g/dl and weighing 35–70 kg. It facilitates a 15-minute infusion (when diluted in saline) and aligns with Anemia Mukt Bharat guidelines as a primary treatment for severe cases.
Who Are The Active Companies Shaping The Iron Deficiency Anemia Therapy Market?
Major companies operating in the iron deficiency anemia therapy market are Sanofi SA, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, CSL Vifor AG, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Luitpold Pharmaceuticals Inc., Covis Pharma GmbH, Pharmacosmos Therapeutics Inc., AFT Pharmaceuticals Ltd., Rockwell Medical Inc., Otsuka Pharmaceutical Co. Ltd., AdvaCare Pharma USA LLC, Apotex Inc., KYE Pharmaceuticals Inc., Emcure Pharmaceuticals Limited, Shield Therapeutics plc, Abbott Laboratories, Bayer AG, Pfizer Inc., Lupin Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd.
Get The Full Iron Deficiency Anemia Therapy Market Report:
Which Region Dominates The Iron Deficiency Anemia Therapy Market By Market Share?
North America was the largest region in the iron deficiency anemia therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the iron deficiency anemia therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Iron Deficiency Anemia Therapy Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Iron Deficiency Anemia Therapy Market 2026, By The Business Research Company
Hemochromatosis Iron Overload Disease Treatment Market Report 2026
Anemia And Other Blood Disorder Drugs Market Report 2026
Chemotherapy Induced Anemia Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
